IL76781A0 - Occular formulation comprising bromocriptine - Google Patents

Occular formulation comprising bromocriptine

Info

Publication number
IL76781A0
IL76781A0 IL76781A IL7678185A IL76781A0 IL 76781 A0 IL76781 A0 IL 76781A0 IL 76781 A IL76781 A IL 76781A IL 7678185 A IL7678185 A IL 7678185A IL 76781 A0 IL76781 A0 IL 76781A0
Authority
IL
Israel
Prior art keywords
occular
bromocriptine
formulation
occular formulation
Prior art date
Application number
IL76781A
Other languages
English (en)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IL76781A0 publication Critical patent/IL76781A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL76781A 1984-10-24 1985-10-22 Occular formulation comprising bromocriptine IL76781A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848426922A GB8426922D0 (en) 1984-10-24 1984-10-24 Galenic formulation

Publications (1)

Publication Number Publication Date
IL76781A0 true IL76781A0 (en) 1986-02-28

Family

ID=10568697

Family Applications (1)

Application Number Title Priority Date Filing Date
IL76781A IL76781A0 (en) 1984-10-24 1985-10-22 Occular formulation comprising bromocriptine

Country Status (15)

Country Link
US (1) US4654345A (pt)
JP (1) JPS61103825A (pt)
AU (1) AU4892885A (pt)
BE (1) BE903483A (pt)
DE (1) DE3536560A1 (pt)
DK (1) DK484785A (pt)
FR (1) FR2571962A1 (pt)
GB (2) GB8426922D0 (pt)
GR (1) GR852545B (pt)
IL (1) IL76781A0 (pt)
IT (1) IT1237360B (pt)
NL (1) NL8502805A (pt)
PT (1) PT81352B (pt)
SE (1) SE8504976L (pt)
ZA (1) ZA858184B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2012532A6 (es) * 1988-07-15 1990-04-01 Cusi Lab Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica.
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
FR2661832A1 (fr) * 1990-05-11 1991-11-15 Corbiere Jerome Procede de stabilisation d'un derive d'ergoline et les compositions pharmaceutiques ainsi obtenues.
US5262422A (en) * 1991-05-02 1993-11-16 Sandoz Ltd. Octahydrobenzo[g]quinoline
FR2680106B1 (fr) * 1991-08-09 1994-03-11 Corbiere Gerome Procede de realisation de formes pharmaceutiques stables d'un derive d'ergoline et les compositions pharmaceutiques ainsi obtenues.
EP0782850A4 (en) * 1994-10-13 1998-03-04 Wakamoto Pharma Co Ltd LYOPHILIZED PREPARATION FOR PRODUCING A REVERSIBLE THERMOGELING MEDICINAL WATER-BASED
GB9600426D0 (en) * 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US6821968B2 (en) 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
DK3445362T3 (da) 2016-04-20 2021-10-11 Veroscience Llc Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
EP4233913A3 (en) 2017-10-18 2023-10-18 VeroScience LLC Improved bromocriptine formulations
PL430675A1 (pl) * 2019-07-23 2021-01-25 Osęka Maciej Bromokryptyna do zastosowania w leczeniu chorób oczu związanych z podwyższonym poziomem śródbłonkowego czynnika wzrostu naczyń (VEGF) oraz kompozycja farmaceutyczna zawierająca bromokryptynę

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (pt) * 1973-05-17 1981-09-03
CH601321A5 (pt) * 1975-01-06 1978-07-14 Sandoz Ag
US4039662A (en) * 1975-12-04 1977-08-02 Alcon Laboratories, Inc. Ophthalmic solution
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
YU216177A (en) * 1977-09-09 1984-02-29 Rudolf Rucman Process for preparing 2-bromo ergosine
YU40533B (en) * 1978-09-04 1986-02-28 Lek Tovarna Farmacevtskih Process for preparing 2-bromoergosinine
DK154607C (da) * 1978-12-21 1989-06-05 Sandoz Ag Fremgangsmaade til fremstilling af en laegemiddelform til oral administration af ergotalkaloider
US4283393A (en) * 1979-03-13 1981-08-11 Merck & Co., Inc. Topical application of interferon inducers
DE3020895A1 (de) * 1979-06-12 1980-12-18 Sandoz Ag Ergopeptinderivate, verfahren zu deren herstellung sowie diese ergopeptinderivate enthaltende pharmazeutischen zusammensetzungen
CA1141663A (en) * 1979-09-06 1983-02-22 Yukihisa Ishii Ophthalmic solution for intraocular pressure adjustment
GB2058746A (en) * 1979-09-20 1981-04-15 Erba Farmitalia 6,7-Secoergolines
DE3033898A1 (de) * 1980-09-09 1982-04-22 Dr. Thilo & Co GmbH, 8021 Sauerlach Arzneimittel zur lokalen behandlung des glaukoms
BE890369A (fr) * 1980-09-18 1982-03-16 Sandoz Sa Nouveaux medicaments a base d'inhibiteurs de la secretion de la prolactine pour le traitement de l'arteriosclerose
US4486416A (en) * 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma

Also Published As

Publication number Publication date
GB8426922D0 (en) 1984-11-28
JPS61103825A (ja) 1986-05-22
BE903483A (fr) 1986-04-21
AU4892885A (en) 1986-07-17
GB8525947D0 (en) 1985-11-27
NL8502805A (nl) 1986-05-16
DE3536560A1 (de) 1986-04-24
SE8504976L (sv) 1986-04-25
IT8548703A0 (it) 1985-10-23
US4654345A (en) 1987-03-31
DK484785A (da) 1986-04-25
GR852545B (pt) 1986-02-18
IT1237360B (it) 1993-05-31
PT81352B (en) 1987-08-05
FR2571962A1 (fr) 1986-04-25
GB2165752A (en) 1986-04-23
ZA858184B (en) 1987-06-24
SE8504976D0 (sv) 1985-10-22
DK484785D0 (da) 1985-10-22
PT81352A (en) 1985-11-01

Similar Documents

Publication Publication Date Title
GB2158345B (en) Wipe
GB8413130D0 (en) Applicator
GB8509690D0 (en) Cosmetic composition
DE3574251D1 (en) An anti-amnestic agent
EP0151984A3 (en) Cosmetic formulation
GB8525947D0 (en) Occular formulation comprising bromocriptine
DE3567374D1 (en) Composition for ophthalmological use
GB8716323D0 (en) Bromocriptine
EP0171836A3 (en) Interferometer interferometer
CY1564A (en) Bromocriptine compositions
EP0181267A3 (en) Fibrinolysis-enhancing agents
GB8615765D0 (en) Cosmetic composition
DE3566485D1 (en) Applicator
GB8406091D0 (en) Duster
GB8409942D0 (en) Applicator
GB8413777D0 (en) Silicone composition
GB8505675D0 (en) Double-ended applicator
GB8417798D0 (en) Examination over surface
GB8415105D0 (en) Sealing-curing agent
PH23266A (en) Bromocriptine compositions
GB8516134D0 (en) Fluorinated norbornylsiloxanes
ZA854139B (en) New use of dihydroergotamine
GB8529238D0 (en) Agents
GB8525135D0 (en) Non-emulsifying agent
IE852617L (en) Occular formulation comprising bromocriptine